MaxCyte, Inc. (NASDAQ:MXCT) EVP Thomas M. Ross Sells 13,531 Shares

MaxCyte, Inc. (NASDAQ:MXCT) EVP Thomas M. Ross sold 13,531 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $4.03, for a total value of $54,529.93. Following the completion of the sale, the executive vice president now directly owns 25,000 shares in the company, valued at approximately $100,750. The sale was disclosed in a legal filing with the SEC, which is available through this link.

MaxCyte Stock Performance

MaxCyte stock opened at $4.11 on Thursday. The business’s fifty day moving average is $4.40 and its two-hundred day moving average is $4.47. The firm has a market cap of $430.81 million, a P/E ratio of -11.74 and a beta of 1.41. MaxCyte, Inc. has a 52 week low of $2.45 and a 52 week high of $5.55.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.68% and a negative net margin of 83.00%. The business had revenue of $11.34 million during the quarter, compared to analysts’ expectations of $7.75 million. On average, equities research analysts predict that MaxCyte, Inc. will post -0.5 earnings per share for the current year.

Hedge Funds Weigh In On MaxCyte

A number of institutional investors have recently modified their holdings of MXCT. PNC Financial Services Group Inc. acquired a new stake in shares of MaxCyte in the fourth quarter valued at approximately $29,000. Russell Investments Group Ltd. bought a new position in MaxCyte in the 1st quarter valued at $28,000. Nisa Investment Advisors LLC boosted its position in MaxCyte by 47,100.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 11,800 shares of the company’s stock valued at $55,000 after buying an additional 11,775 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of MaxCyte by 350.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock valued at $56,000 after buying an additional 9,323 shares during the period. Finally, Victory Capital Management Inc. raised its position in shares of MaxCyte by 23.0% during the fourth quarter. Victory Capital Management Inc. now owns 12,316 shares of the company’s stock worth $58,000 after acquiring an additional 2,306 shares during the last quarter. 68.81% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Stephens restated an “overweight” rating and issued a $11.00 target price on shares of MaxCyte in a research note on Tuesday, April 23rd. BTIG Research reduced their price target on shares of MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a research note on Wednesday, March 13th.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.